Watch full video<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, explains the rationale behind cell therapies for diabetes, and the specific issues related to the Type I and Type II forms.<\/p>\n","protected":false},"author":1,"featured_media":2498,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"aioseo_notices":[],"yoast_head":"\n
Stem cell therapy for Diabetes: Type I vs Type II - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics<\/title>\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\n